2024年10月4日,Nature在其官网头条位置,报道了一项由中国科学家团队在Cell杂志上发表的研究成果-World-first therapy using donor cells sends autoimmune diseases into remission(世界上第一个使用供体细胞的疗法可以缓解自身免疫性疾病)。 文献解读 文章:Allogeneic CD19-targeted CAR-T therapy in patients with seve...
近期,Nature期刊上发表了题为“Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL”的研究论文,旨在探究基于CRISPR–Cas9技术的非病毒、基因特异性靶向CAR-T细胞的安全性和有效性。 图源| nature....
[6] Mougiakakos, D. et al. CD19-targeted CAR T cells in refractory systemic lupuserythematosus. N. Engl. J. Med. 385, 567–569 (2021). [7] . Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor efects and ...
在一项新的研究中,来自德国埃朗根-纽伦堡大学的研究人员首次在一名患有严重系统性红斑狼疮(SLE)的20岁女性身上测试了经过基因改造的CAR-T细胞疗法,发现这可使她所患的重症狼疮迅速得到缓解,在六周后没有明显的副作用。相关研究结果发表在2021年8月5日的NEJM期刊上,论文标题为“CD19-Targeted CAR T Cells in Refrac...
3.Baker DJ, June CH. CAR T therapy extends its reach to autoimmune diseases. Cell. 2022 Nov 23;185(24):4471-4473. doi: 10.1016/j.cell.2022.10.026. 4.Bergmann C, Müller F,et al. Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. Ann Rhe...
CD19抗体往往稳定表达于B-ALL,其作为靶点的嵌合抗原受体T细胞(CAR-T)细胞治疗时,具有非常高的缓解率[7],但该患者肿瘤细胞出现CD19靶点阴性,使其不适用CD19-CAR-T治疗[8],并且加大对治疗后期MRD的监测难度。 该患者实际化疗方案为VCR 2mg d1,CTX 1.6g d1,Pred 60mg d1-24,利妥昔单抗0.6g d11。骨髓抑...
Wenbin Xiao等人以CD19 CAR-T治疗9名5～25岁复发难治性B-ALL患者,发现在这些患者在治疗过程中出现一类不寻常的造血前体细胞,在论文《Early recovery of circulating immature B cells in B-lymphoblastic leukemia patients after CD19 targeted CAR T cell therapy: a pitfall for minimal residual disease detection...
CD19-targeted CAR T cells have induced complete remissions of disease in up to 90% of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), who have an expected complete response rate of 30% in response to chemotherapy. The high efficacy of CAR T cells in B-...
12、CD19 CAR-T细胞在体内增强了GCC CAR-T细胞的细胞毒性 小结 大家都知道,实体瘤疗效不佳的其中一个原因就是CART扩增不良,这项研究创新地提出了刺激CART细胞扩增地新方法,为未来CRC和其他实体瘤的治疗提供了新的思路! 参考文献: Chen, Naifei et al. “Chimeric Antigen Receptor T Cells Targeting CD19 and ...
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells Nature, 2018 背景 CAR-T (chimaeric antigen receptor T cells) 已成功的用于治疗B淋巴细胞相关的恶性肿瘤。在治疗过程中,T细胞从患者体内取出,并在体外进行改造(如慢病毒感染)使T细胞表达表面嵌合抗原受体(CAR),当细胞被转移至体内...